HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,300.00
+10.00 (0.23%)
Apr 28, 2026, 3:30 PM KST
-30.76%
Market Cap 523.94B
Revenue (ttm) 45.75B
Net Income (ttm) -99.79B
Shares Out 121.85M
EPS (ttm) -819.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 237,511
Average Volume 377,872
Open 4,300.00
Previous Close 4,290.00
Day's Range 4,240.00 - 4,340.00
52-Week Range 3,105.00 - 6,690.00
Beta -0.01
RSI 54.09
Earnings Date May 14, 2026

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.